Evidence map›Paper›PMID 34674065›Full record

ArticleSurgical case reports2021

Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers.

Megumi Takaoka, Shozo Ohsumi, Yuichiro Miyoshi, Mina Takahashi, Seiki Takashima, Kenjiro Aogi, Teruhiko Shimizu, Norihiro Teramoto, Yasuko Yamamoto, Miki Okamura

Open access · goldAbstract read
In one paragraph

Article in Surgical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Megumi TakaokaDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan. megumi.tkk0731@gmail.com.ORCID http://orcid.org/0000-0002-6402-4058
Shozo OhsumiDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Yuichiro MiyoshiDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Mina TakahashiDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Seiki TakashimaDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Kenjiro AogiDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Teruhiko ShimizuDepartment of Radiology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Norihiro TeramotoDepartment of Pathology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Yasuko YamamotoDepartment of Familial Tumor, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Miki OkamuraDepartment of Familial Tumor, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umenomoto-machi, Matsuyama, 791-0280, Japan.
Shikoku Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance imaging (MRI) is recommended for BRCA1/2 mutation carriers aged over 25 years as a secondary prevention of breast cancer. However, breast MRI surveillance is rarely performed in Japan, and only four cases of breast cancer diagnosis triggered by MRI surveillance have been reported. CASE PRESENTATION: At our hospital, MRI triggered the diagnosis of breast cancer in four cancer-free BRCA1/2 mutation carriers. In one of our four cases, although MRI showed only a 3-mm focus, we could diagnose breast cancer by shortening the surveillance interval considering the patient's high-risk for developing breast cancer.

conclusionsImage-guided biopsy, including MRI-guided biopsy, depending on the size of the lesion, and shorter surveillance intervals are useful when there are potentially malignant findings on breast MRI surveillance for cancer-free patients with HBOC.

Indexed as

BRCABreast cancerHereditary breast and ovarian cancer syndromeMRI surveillance

Identifiers

PMID34674065
PMCPMC8531180
OpenAlexW3207207020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.